Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89


Differential presentation of protein interaction surfaces on the androgen receptor defines the pharmacological actions of bound ligands.

Norris JD, Joseph JD, Sherk AB, Juzumiene D, Turnbull PS, Rafferty SW, Cui H, Anderson E, Fan D, Dye DA, Deng X, Kazmin D, Chang CY, Willson TM, McDonnell DP.

Chem Biol. 2009 Apr 24;16(4):452-60. doi: 10.1016/j.chembiol.2009.01.016.


Linking ligand-induced alterations in androgen receptor structure to differential gene expression: a first step in the rational design of selective androgen receptor modulators.

Kazmin D, Prytkova T, Cook CE, Wolfinger R, Chu TM, Beratan D, Norris JD, Chang CY, McDonnell DP.

Mol Endocrinol. 2006 Jun;20(6):1201-17. Epub 2006 Mar 30.


Inhibition of prostate cancer cell growth by second-site androgen receptor antagonists.

Joseph JD, Wittmann BM, Dwyer MA, Cui H, Dye DA, McDonnell DP, Norris JD.

Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12178-83. doi: 10.1073/pnas.0900185106. Epub 2009 Jul 2.


Structural basis for accommodation of nonsteroidal ligands in the androgen receptor.

Bohl CE, Miller DD, Chen J, Bell CE, Dalton JT.

J Biol Chem. 2005 Nov 11;280(45):37747-54. Epub 2005 Aug 29.


In vitro and in vivo structure-activity relationships of novel androgen receptor ligands with multiple substituents in the B-ring.

Chen J, Hwang DJ, Chung K, Bohl CE, Fisher SJ, Miller DD, Dalton JT.

Endocrinology. 2005 Dec;146(12):5444-54. Epub 2005 Sep 15.


Ligand binding to the androgen receptor induces conformational changes that regulate phosphatase interactions.

Yang CS, Xin HW, Kelley JB, Spencer A, Brautigan DL, Paschal BM.

Mol Cell Biol. 2007 May;27(9):3390-404. Epub 2007 Feb 26.


Differential modulation of androgen receptor transcriptional activity by the nuclear receptor co-repressor (N-CoR).

Berrevoets CA, Umar A, Trapman J, Brinkmann AO.

Biochem J. 2004 May 1;379(Pt 3):731-8.


Inhibitors of androgen receptor activation function-2 (AF2) site identified through virtual screening.

Axerio-Cilies P, Lack NA, Nayana MR, Chan KH, Yeung A, Leblanc E, Guns ES, Rennie PS, Cherkasov A.

J Med Chem. 2011 Sep 22;54(18):6197-205. doi: 10.1021/jm200532b. Epub 2011 Aug 29.


LINE-1 ORF-1p functions as a novel androgen receptor co-activator and promotes the growth of human prostatic carcinoma cells.

Lu Y, Feng F, Yang Y, Gao X, Cui J, Zhang C, Zhang F, Xu Z, Qv J, Wang C, Zeng Z, Zhu Y, Yang Y.

Cell Signal. 2013 Feb;25(2):479-89. doi: 10.1016/j.cellsig.2012.11.004. Epub 2012 Nov 12.


Ku is a novel transcriptional recycling coactivator of the androgen receptor in prostate cancer cells.

Mayeur GL, Kung WJ, Martinez A, Izumiya C, Chen DJ, Kung HJ.

J Biol Chem. 2005 Mar 18;280(11):10827-33. Epub 2005 Jan 7.


Impaired helix 12 dynamics due to proline 892 substitutions in the androgen receptor are associated with complete androgen insensitivity.

Elhaji YA, Stoica I, Dennis S, Purisima EO, Lumbroso R, Beitel LK, Trifiro MA.

Hum Mol Genet. 2006 Mar 15;15(6):921-31. Epub 2006 Jan 31. Erratum in: Hum Mol Genet. 2006 May 1;15(9):1561. Lumbroso, Rose [added]; Beitel, Lenore K [added].


Androgen receptor interacts with a novel MYST protein, HBO1.

Sharma M, Zarnegar M, Li X, Lim B, Sun Z.

J Biol Chem. 2000 Nov 10;275(45):35200-8.


Identification of novel androgen receptor antagonists using structure- and ligand-based methods.

Li H, Ren X, Leblanc E, Frewin K, Rennie PS, Cherkasov A.

J Chem Inf Model. 2013 Jan 28;53(1):123-30. doi: 10.1021/ci300514v. Epub 2013 Jan 16.


Identification and characterization of a ligand-regulated nuclear export signal in androgen receptor.

Saporita AJ, Zhang Q, Navai N, Dincer Z, Hahn J, Cai X, Wang Z.

J Biol Chem. 2003 Oct 24;278(43):41998-2005. Epub 2003 Aug 15.


A multi-parameter imaging assay identifies different stages of ligand-induced androgen receptor activation.

van Royen ME, van de Wijngaart DJ, Cunha SM, Trapman J, Houtsmuller AB.

Cytometry A. 2013 Sep;83(9):806-17. doi: 10.1002/cyto.a.22284. Epub 2013 Apr 12.


Androgen receptor ligand-binding domain interaction and nuclear receptor specificity of FXXLF and LXXLL motifs as determined by L/F swapping.

Dubbink HJ, Hersmus R, Pike AC, Molier M, Brinkmann AO, Jenster G, Trapman J.

Mol Endocrinol. 2006 Aug;20(8):1742-55. Epub 2006 Apr 20.


Supplemental Content

Support Center